TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29782479

Group type: EXPERIMENTAL
Intervention: Multicomponent balance and resistance training intervention (once weekly supervised group sessions with home sessions encouraged twice weekly)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Multicomponent balance and resistance training intervention
Number of subjects: 33
Study: 29920171

Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraception (LARC)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Discontinuation of LARC
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Concerns about insertion and removal of LARC
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Affordability of LARC
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Regret from trying LARC
Number of subjects: 34
Study: 28096020

Group type: EXPERIMENTAL
Intervention: Psychoeducation program (PEP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 25249313

Group type: EXPERIMENTAL
Intervention: Gadobutrol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Gd‐DOTA (0.1 mmol/kg BW)
Number of subjects: 52
Study: 23811645

Group type: EXPERIMENTAL
Intervention: Cerasorb(®)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cerasorb(®) and BioMend Extend™
Number of subjects: 10
Study: 21876061

Group type: EXPERIMENTAL
Intervention: 100 mg micafungin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 300 mg micafungin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Micafungin (both doses)
Number of subjects: 36
Study: 18053051

Group type: EXPERIMENTAL
Intervention: Alpha-hydroxy acid (30% glycolic acid)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Beta-hydroxy acid (30% salicylic acid)
Number of subjects: 20
Study: 16414419

Group type: EXPERIMENTAL
Intervention: Sunny Days, Healthy Ways curriculum
Number of subjects: 2038
Study: 12942300

Group type: COMPARATOR
Intervention: 81 kVp (CEC)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 96 kVp (non-CEC)
Number of subjects: 59

Group type: COMPARATOR
Intervention: 90 kVp (CEC)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 102 kVp (non-CEC)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: All kVp values
Number of subjects: 59
Study: 10729306

Group type: EXPERIMENTAL
Intervention: Sub‐Tenon's block with 3 ml lignocaine 2%/adrenaline 1:200 000 + 30 IU/ml of hyaluronidase
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sub‐Tenon's block with 3 ml lignocaine 2%/adrenaline 1:200 000 alone
Number of subjects: 150
Study: 9020426

Group type: EXPERIMENTAL
Intervention: Lodoxamide tromethamine 0.1%
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1390305

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (rIFN alfa‐2a)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a + vinblastine (VLB)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Both treatment arms
Number of subjects: 178

Group type: COMPARATOR
Intervention: Performance status 0
Number of subjects: 178

Group type: COMPARATOR
Intervention: Performance status 1
Number of subjects: 178

Group type: COMPARATOR
Intervention: Performance status 2
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Combination treatment (rIFN alfa‐2a + VLB)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Monotherapy (rIFN alfa‐2a)
Number of subjects: 178
Study: 3902068

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase infusion
Number of subjects: 302

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 302
Study: 29595659

Group type: EXPERIMENTAL
Intervention: Radial artery pressure pulse wave treatment in stroke patients with hemiplegia
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (28 matched patients)
Number of subjects: 84
Study: 29081178

Group type: EXPERIMENTAL
Intervention: Weight management guidance and adjusted diuretic drugs regimen based on body weight changes
Number of subjects: 350

Group type: COMPARATOR
Intervention: Routine medical care post discharge (Control)
Number of subjects: 350
Study: 26314275

Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg fortnightly after induction)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Thiopurines (azathioprine 2 mg/kg/day or mercaptopurine 1.5 mg/kg/day)
Number of subjects: 101
Study: 23216710

Group type: EXPERIMENTAL
Intervention: Fondaparinux thromboprophylaxis
Number of subjects: 92

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) thromboprophylaxis
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Strong IgG antibodies (≥ 1.0 OD units and ≥ 2× baseline)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No strong IgG antibodies
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Postoperative anti-PF4/heparin IgG responses
Number of subjects: 92
Study: 21624100

Group type: EXPERIMENTAL
Intervention: Adrenaline (0.4 μg min m(‐2))
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study: 18945995

Group type: EXPERIMENTAL
Intervention: Cinacalcet and low-dose vitamin D (Cinacalcet-D)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Flexible vitamin D alone (Flex-D)
Number of subjects: 173
Study: 16467100

Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg plus sirolimus 5 mg (not on EIAEDs)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Gefitinib 1000 mg plus sirolimus 10 mg (on EIAEDs)
Number of subjects: 34
Study: 14734876

Group type: EXPERIMENTAL
Intervention: Ready-to-use food (RTUF) for 12 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Maize and soy flour for 12 weeks
Number of subjects: 61
Study: 11314676

Group type: EXPERIMENTAL
Intervention: Oral cocaine (100 mg/70 kg)
Number of subjects: 9
Study: 9312761

Group type: EXPERIMENTAL
Intervention: Essential Hypertension (HT)
Number of subjects: 108
Study: 8287998

Group type: EXPERIMENTAL
Intervention: sectoral, scatter laser photocoagulation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 88
Study: 3809244

Group type: EXPERIMENTAL
Intervention: L-tryptophan (4 tablets of 500 mg/day for 14 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phenylalanine (4 tablets of 500 mg/day for 14 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (4 placebo tablets/day for 14 days)
Number of subjects: 60
Study: 31302695

Group type: EXPERIMENTAL
Intervention: Belimumab (i.v. every 4 weeks plus standard therapy)
Number of subjects: 738
Study: 28525723

Group type: EXPERIMENTAL
Intervention: Chest Pain Choice (CPC) decision aid
Number of subjects: 898

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 898
Study: 27678426

Group type: EXPERIMENTAL
Intervention: Low advanced glycation end products diet (L‐dAGEs)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard advanced glycation end products diet (S‐dAGEs)
Number of subjects: 62
Study: 24886920

Group type: EXPERIMENTAL
Intervention: HFM+RE
Number of subjects: 9

Group type: COMPARATOR
Intervention: HFM
Number of subjects: 9
Study: 21889297

Group type: EXPERIMENTAL
Intervention: Teachers with self-reported voice problems
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teachers with self-reported voice health
Number of subjects: 0
Study: 20136661

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 600

Group type: COMPARATOR
Intervention: Abacavir
Number of subjects: 600
Study: 18354708

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency lesioning of the dorsal root ganglion/segmental nerve
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Pulsed and continuous radiofrequency lesioning
Number of subjects: 76
Study: 16193347

Group type: EXPERIMENTAL
Intervention: Etidronate therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 11709789

Group type: EXPERIMENTAL
Intervention: BBG2Na 10 microg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: BBG2Na 100 microg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: BBG2Na 300 microg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: BBG2Na (all doses)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 108
Study: 9051434

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray 0.14 mg/nostril twice daily (0.56 mg/day)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 125
Study: 8091174

Group type: EXPERIMENTAL
Intervention: Lidocaine (2.0 ml 2%)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Articaine (2.0 ml 4%)
Number of subjects: 2
Study: 3592320

Group type: EXPERIMENTAL
Intervention: 12-hour cefazolin (4 intravenous injections of 1 g cefazolin over 12 hours)
Number of subjects: 159

Group type: COMPARATOR
Intervention: 36-hour cefazolin (12 doses over 36 hours)
Number of subjects: 159
Study: 29502160

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) for BMS
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) for BMS
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) for SOB
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) for SOB
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (healthy female subjects)
Number of subjects: 44
Study: 26552942

Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg/day
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 23883379

Group type: EXPERIMENTAL
Intervention: 100 mg semagacestat
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: 140 mg semagacestat
Number of subjects: 1537

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1537
Study: 21538515

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 19655819

Group type: EXPERIMENTAL
Intervention: Combination therapy with olmesartan medoxomil/HCTZ 20/25 mg/day
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Combination therapy with olmesartan medoxomil/HCTZ 40/12.5 mg/day
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Combination therapy with olmesartan medoxomil/HCTZ 40/25 mg/day
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: HCTZ 12.5 or 25 mg/day
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 10, 20, or 40 mg/day
Number of subjects: 502
Study: 16273313

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) + BCNU + standard radiation therapy (SRT)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) + BCNU + accelerated radiation therapy (ART)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Carmustine (BCNU) + standard radiation therapy (SRT)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Carmustine (BCNU) + accelerated radiation therapy (ART)
Number of subjects: 451
Study: 15222409

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11259892

Group type: EXPERIMENTAL
Intervention: Mepivacaine 1% (1 mL/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% (1 mL/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mixture of mepivacaine 1% and bupivacaine 0.25% (0.5 mL/kg each)
Number of subjects: 60
Study: 9219213

Group type: EXPERIMENTAL
Intervention: Ramp incremental rate trials
Number of subjects: 10

Group type: COMPARATOR
Intervention: Constant power trials
Number of subjects: 10
Study: 8356413

Group type: EXPERIMENTAL
Intervention: Rifamycin SV
Number of subjects: 87

Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 87
Study: 3278500

Group type: EXPERIMENTAL
Intervention: Combined spinal epidural (CSE) block
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural block
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined spinal epidural (CSE) block and Epidural block
Number of subjects: 30
Study: 29682897

Group type: EXPERIMENTAL
Intervention: HR‐ADM plus standard of care (SOC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HR‐ADM plus SOC
Number of subjects: 80
Study: 28054235

Group type: EXPERIMENTAL
Intervention: Heated Humidified High-Flow Nasal Cannula (HHHFNC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 49
Study: 26597979

Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy (EGDT)
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Usual resuscitation
Number of subjects: 1260
Study: 23611076

Group type: EXPERIMENTAL
Intervention: Trauma Affect Regulation: Guide for Education and Therapy (TARGET)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Supportive Group Therapy (SGT)
Number of subjects: 72
Study: 21301135

Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride plus conventional therapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Metoprolol plus conventional therapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 53
Study: 18466804

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) for 2 months followed by 6 months of self-regulated training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 23036114

Group type: EXPERIMENTAL
Intervention: Standard care plus ≥64-multidetector computed tomography coronary angiography and coronary calcium score
Number of subjects: 4138

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 4138
Study: 15711898

Group type: EXPERIMENTAL
Intervention: Sonic Speed toothbrush in conjunction with the electric interdental cleaning device Flosser FL‐110 (Water Pik)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual interX short brush‐head toothbrush (elmex)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sonic Speed SR‐100E sonic toothbrush (Water Pik)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sonic Speed sonic toothbrush in conjunction with multi‐floss 3‐phase dental floss (elmex)
Number of subjects: 40
Study: 12183280

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Voriconazole at 10.4 +/- 4.3 micro g/ml
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 11477859

Group type: EXPERIMENTAL
Intervention: RT plus Chinese herbal medicine
Number of subjects: 50

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 50
Study: 7806958

Group type: EXPERIMENTAL
Intervention: Students with learning disabilities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Students without learning disabilities
Number of subjects: 0
Study: 2514651

Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg daily for 3 months
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg daily for 3 months
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (during single-blind period)
Number of subjects: 72
Study: 1097345

Group type: EXPERIMENTAL
Intervention: Total liver extract
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29192837

Group type: EXPERIMENTAL
Intervention: Nordic Hamstring exercise (NHE)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Do-as-usual control group (CG)
Number of subjects: 35
Study: 28285423

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional osteotomy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 26705233

Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate Gel (SHG group)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Chitosan (CH group)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (CON group)
Number of subjects: 114
Study: 23117218

Group type: EXPERIMENTAL
Intervention: Adjuvant Occupational Therapy (OT)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 117
Study: 21048770

Group type: EXPERIMENTAL
Intervention: diet+PS (2 g/day of phytosterols)
Number of subjects: 75

Group type: COMPARATOR
Intervention: diet (control group)
Number of subjects: 75
Study: 18506005

Group type: EXPERIMENTAL
Intervention: RB006 (15 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: RB006 (30 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: RB006 (50 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: RB006 (75 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: RB007 (antidote)
Number of subjects: 50
Study: 16517572

Group type: EXPERIMENTAL
Intervention: Breathing exercises focusing on shallow nasal breathing
Number of subjects: 57

Group type: COMPARATOR
Intervention: Non‐specific upper body exercises
Number of subjects: 57
Study: 12705316

Group type: EXPERIMENTAL
Intervention: Culturally and linguistically appropriate session on infant immunization
Number of subjects: 352

Group type: COMPARATOR
Intervention: Session on prevention of Sudden Infant Death Syndrome
Number of subjects: 352
Study: 10758792

Group type: EXPERIMENTAL
Intervention: Pulsatile oxytocin infusion
Number of subjects: 560

Group type: COMPARATOR
Intervention: Continuous oxytocin infusion
Number of subjects: 560
Study: 8970215

Group type: EXPERIMENTAL
Intervention: Amoxicillin (20 mg/kg once daily)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 1375873

Group type: EXPERIMENTAL
Intervention: OK-432 (intratumoral injection)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (non-injected)
Number of subjects: 14
Study: 6385693

Group type: EXPERIMENTAL
Intervention: Gentamicin and Tobramycin with peak levels of 7 micrograms/ml or greater
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Amikacin with peak levels of 28 micrograms/ml or greater
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Overall mean peak levels of 6 micrograms/ml or greater for Gentamicin and Tobramycin
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Overall mean peak levels of 24 micrograms/ml or greater for Amikacin
Number of subjects: 37
Study: 29368187

Group type: EXPERIMENTAL
Intervention: Fluvastatin with green tea extract (GTE) containing 150 mg of EGCG
Number of subjects: 11

Group type: COMPARATOR
Intervention: Brewed green tea
Number of subjects: 11

Group type: COMPARATOR
Intervention: Green tea extract (GTE)
Number of subjects: 11
Study: 26858080

Group type: EXPERIMENTAL
Intervention: 6-month DAPT
Number of subjects: 1829

Group type: COMPARATOR
Intervention: 12-month DAPT
Number of subjects: 1829
Study: 25603389

Group type: EXPERIMENTAL
Intervention: Dexamethasone 2.5 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Dexamethasone 5.0 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Dexamethasone 7.5 mg
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (0.0 mg dexamethasone)
Number of subjects: 144
Study: 23061407

Group type: EXPERIMENTAL
Intervention: Orlistat and sibutramine treatment
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (without T allele)
Number of subjects: 101
Study: 20090325

Group type: EXPERIMENTAL
Intervention: Erosion without dental plaque (EO)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Erosion with plaque (EP)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Cariogenic challenge with plaque (CO)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Erosion plus cariogenic challenge (EC)
Number of subjects: 4
Study: 18188033

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg twice daily)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g three times a day)
Number of subjects: 62
Study: 16763848

Group type: EXPERIMENTAL
Intervention: ADCON‐L Gel (ALG)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Preclude Spinal Membrane (PSM)
Number of subjects: 31
Study: 15230300

Group type: EXPERIMENTAL
Intervention: High dose glucocorticoids and immunosuppressive agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical outcomes survey short form‐36 (SF-36)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACR/SLICC damage index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responder indices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Area under the curve analysis
Number of subjects: 0
Study: 12439362

Group type: EXPERIMENTAL
Intervention: Aggressive saline hydration with the aim of keeping urine output over 150 mL/hour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-osmolality contrast agents with minimal volume
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine DA1 agonist fenoldopam
Number of subjects: 0
Study: 9133770

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 7962669

Group type: EXPERIMENTAL
Intervention: 50 mg S(‐)‐atenolol (SATN)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100 mg racemic atenolol (RSATN)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: S(‐)‐atenolol (SATN)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: racemic atenolol (RSATN)
Number of subjects: 8
Study: 3679915

Group type: EXPERIMENTAL
Intervention: Neutron therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 0
Study: 31575336

Group type: EXPERIMENTAL
Intervention: 384 preprocessing strategies applied to [11C]DASB-PET data
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Preprocessing strategies with motion correction
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Preprocessing strategies without motion correction
Number of subjects: 30
Study: 30075691

Group type: EXPERIMENTAL
Intervention: Automated species-level classification of echolocation clicks using supervised step-wise discriminant analysis and clustering routines.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spectral clustering tested on clicks from encounters of beaked, sperm, and pilot whales.
Number of subjects: 0
Study: 27103175

Group type: EXPERIMENTAL
Intervention: gedatolisib (PF-05212384)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: PF-04691502
Number of subjects: 58
Study: 26202325

Group type: EXPERIMENTAL
Intervention: Robot-supported upper limb training (3 weekly sessions of 30 min for 8 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 17